天士力：获药物临床试验批准通知书

Core Viewpoint - The announcement indicates that Tianjin Tasly Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of TSL2109 capsules, a new dual-target small molecule inhibitor for advanced solid tumors [1] Company Summary - Jiangsu Diyi, a wholly-owned subsidiary of Tianjin Tasly, is responsible for the development of TSL2109 capsules in collaboration with China Pharmaceutical University [1] - The total investment in the research and development of TSL2109 capsules has reached RMB 24.6251 million [1] Industry Summary - The approval for clinical trials highlights the ongoing innovation in the pharmaceutical industry, particularly in the development of new cancer therapies [1] - The development process of new drugs is characterized by uncertainty, and future market competition dynamics are expected to change [1]